scientists just found that combining KEYTRUDA and WELIREG after surgery cuts the risk of clear cell kidney cancer (ccRCC) returning or spreading by 28%. these are new types of drugs, an immune checkpoint blocker and a growth pathway inhibitor.
The FDA has approved a new combination treatment for certain patients with clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer. This dual therapy, involving KEYTRUDA (or KEY
